# A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

> **NCT05941507** · PHASE1,PHASE2 · RECRUITING · sponsor: **LigaChem Biosciences, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** LCB84
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05941507
- **Lead sponsor:** LigaChem Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941507, "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05941507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*